Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from GlobalNewsWire (2014)

16:01 EST 21st January 2019 | BioPortfolio

Here are the most relevant search results for "GlobalNewsWire (2014)" found in our extensive news archives from over 250 global news sources.

More Information about GlobalNewsWire (2014) on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about GlobalNewsWire (2014) for you to read. Along with our medical data and news we also list GlobalNewsWire (2014) Clinical Trials, which are updated daily. BioPortfolio also has a large database of GlobalNewsWire (2014) Companies for you to search.

Showing News Articles 1–25 of 4,400+ from GlobalNewsWire (2014)

Monday 21st January 2019

INVENTIVA : Voting Results from the General Meeting Held on January 18, 2019

Voting Results from the General Meeting Held on January 18, 2019 Daix (France), January 21st, 2019 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced, in accordance with the terms of Article ...

GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019

GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019 Lille (France); Cambridge (Massachusetts, United States) - January 21, 2019 -GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announces its provisional financial calendar for 20...

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase  I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been pub...

Friday 18th January 2019

Xbrane Biopharma announces acceptance of initiation of Xlucane clinical trial in the US

Press release2019-01-18 The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial with Xlucane, a ranibizumab (Lucentis®) biosimilar candidate. "It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee...

Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine

COPENHAGEN, Denmark, January 18, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN® smallpox vaccine. The option, valued at USD 44 million, will cover qualification of the new fill-finish facility, currentl...

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting

LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled "TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemoth...

Thursday 17th January 2019

Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes

FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes PARIS and THE WOODLANDS, TX - January 17, 2019 - The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Zynquista(TM)* (sotagliflozin) outweighed...

Virbac : 2018 annual revenue grew by +4.5% at constant exchange rates

2018 annual revenue grew by +4.5% at constant exchange rates KEY FIGURES Revenue 2018Provisional   €868.8million

Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids DUBLIN - January 17, 2019 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the SynchroMed(TM) II...

Ossur Hf : Q4&FY 2018 Results - Conference call Tuesday 5 February at 9:00 CET

Announcement no. 03/201817 January 2019 Conference call on Tuesday 5 February at 9:00 CET / 8:00 GMT / 3:00 EDT Össur will publish its financial results for Q4&FY 2018 prior to market opening on Tuesday 5 February. That same day at 9:00 CET, Össur will host a conference call where Jon Sigurdsson, President and CEO, and Sveinn Solvason, CFO, will present and discuss the results of the ...

Nicox Fourth Quarter 2018 Business Update and Financial Highlights

Press ReleaseNicox Fourth Quarter 2018 Business Update and Financial Highlights ............................................... Total VYZULTA® prescriptions for the fourth quarter 2018 up 47% compared to the third quarter 2018  Quarterly net reven

DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, January 17, 2019 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between...

FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer

F. Hoffmann-La Roche Ltd / FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Basel, 17 January 2019 - Roc...

Wednesday 16th January 2019

Aino Health AB (publ): Aino Health signs agreement with global customer service company

January 16 2019Aino Health has signed an agreement regarding Aino HealthManager with a global company in customer service. The agreement encompasses more than 450 new licenses for Aino's SaaS solution HealthManager in Sweden and Norway. The agreement pertains to a pilot project running for six months within parts of the Swedish and Norwegian operations. After that, there is an...

VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

 Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019 Following award of a new IXIARO® supply contract with the U.S. Department of Defense, Valneva provides initial product sales guidance 2019 Saint Herblain (France), January 16, 2019 - Valneva SE ("Valneva" or "the Company"), a biotech company developing and commercializin...

Tuesday 15th January 2019

Medtronic Launches Mobile App That Communicates Directly with World's First Smartphone-Connected Pacemakers

MyCareLink Heart(TM) Mobile App Allows Pacemaker Patients to Easily Stay Connected with Their Clinics DUBLIN - January 15, 2019 - Medtronic plc (NYSE:MDT) today announced the launch of its MyCareLink Heart(TM) mobile app to support the world's first and only portfolio of pacemakers that can communicate directly with patients' smartphones and tablets. Compatible with Medt...

Achim von Leoprechting promoted to become CEO of Tecan after retirement of David Martyr

Tecan Group AG / Achim von Leoprechting promoted to become CEO of Tecan after retirement of David Martyr . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Männedorf, Switzerland, January 15, 2019 - The Tecan Group (SIX Swiss Exchange: TECN) announced today the retirement of Tecan CEO Dr David Martyr after 6 1...

Monday 14th January 2019

Nexstim Plc Depression Therapy Business Update

Company announcement, Helsinki, 14 January 2019 at 09.00 Nexstim Plc Depression Therapy Business Update Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), has shifted its resources and focus during year 2018 to...

Thursday 10th January 2019

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2018

Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Charenton-le-Pont, France (January 10, 2019 - 6:00 pm) As of December 31, 2018, shares and voting rights outstanding of EssilorLuxottica, t...

LIDDS employs Head of Business Development

LIDDS announces today that Markus Thor has been appointed as Head of Business Development and will join the company in March 2019. The employment is a consequence of the enlarged project portfolio and the broad interest from the pharma industry for the NanoZolid technology. Markus Thor has a thorough experience in business development and out-licensing from companies like Biovitrum, Kance...

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 24th tranche of investment today

    Amsterdam, The Netherlands - 10 January 2019 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 24th   Tranche of EUR 230,000 is issued as a private placement of 23 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 778,195 share subscription warrants attached (the "Warrants"), under t...

Wednesday 9th January 2019

New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder

New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic p...

Medtronic Foundation Recognizes 12 Bakken Invitation Honorees for Driving Positive Change in Healthcare

Program Celebrates the Legacy of Medtronic Co-Founder Earl Bakken and Other Outstanding Patient Advocates Around the World MINNEAPOLIS and Kona, Hawaii - January 9, 2019 - The Medtronic Foundation today announced 12 individuals from around the world as recipients of the 2018 Bakken Invitation. This Medtronic Foundation program recognizes and connects people who "live on, giv...

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation

ORION CORPORATION      STOCK EXCHANGE RELEASE     9 JANUARY 2019 at 12.40 EET Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation The Nomination Committee of Orion Corporation has on 9 January 2019 given its recommendation to the Board of Directors of the company for the proposal to...

Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA)

Basilea Pharmaceutica AG / Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA) . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. 21% objective response rate with six confirmed partial responses from 29 e...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks